Sensus Healthcare to Participate in Two Upcoming Investor Conferences on November 30th and December 1st

Wednesday, November 16, 2016 General News J E 4
-- Evercore ISI MedTools Investor Conference in Boston, MA

BOCA RATON, Fla., Nov. 16, 2016 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy (SRT), today announced that Joe Sardano, CEO and Arthur Levine, CFO will participate in two upcoming investor conferences:

  • Evercore ISI MedTools Investor Conference to be held at the Boston Harbor Hotel in Boston, MA on Wednesday, November 30, 2016.
  • Drexel Hamilton's Emerging Growth Conference to be held at the Drexel Hamilton Offices, 77 Water Street in New York, NY on Thursday, December 1, 2016. Joe Sardano will present at 1:30pm ET. The presentation will be available via live audio webcast and archived replay on Sensus' investor relations website at

Investors attending the conferences who wish to meet with management for a one-on-one meeting should notify their appropriate contact.

For more information and registration, please visit the conference websites: Evercore ISI and Drexel Hamilton.

About Sensus Sensus Healthcare, Inc. is a medical device company that is committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy x-ray radiation technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development activities. Sensus has successfully incorporated the SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, the SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit

Investor Relations:Jeffrey Goldberger / Allison Soss KCSA Strategic CommunicationsPhone: 212-896-1249 / 212-896-1267Email: / 


To view the original version on PR Newswire, visit:

SOURCE Sensus Healthcare



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s Publishes New SNNLive Video Inter...
Jindal-Ipas Joint Consultation Deliberates on Safe...